IPILIMUMAB

43846 reported adverse events

Drug classes: CTLA-4-directed Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking IPILIMUMAB:

# Side effect Count
0 DEATH 4577
1 MALIGNANT NEOPLASM PROGRESSION 3853
2 DIARRHOEA 3159
3 OFF LABEL USE 2616
4 COLITIS 2337
5 PYREXIA 2100
6 RASH 1845
7 FATIGUE 1715
8 NAUSEA 1401
9 INTENTIONAL PRODUCT USE ISSUE 1345
See all common reactions for IPILIMUMAB

IPILIMUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HYPOPHYSITIS 1086 0.5395
1 LYMPHOCYTIC HYPOPHYSITIS 143 0.5181
2 IMMUNE-MEDIATED HYPOPITUITARISM 15 0.4545
3 IMMUNE-MEDIATED UVEITIS 82 0.4481
4 AUTOIMMUNE COLITIS 284 0.4403
5 IMMUNE-MEDIATED HYPOPHYSITIS 186 0.4124
6 IMMUNE-MEDIATED GASTROINTESTINAL DISORDER 17 0.3953
7 IMMUNE-MEDIATED ENDOCRINOPATHY 51 0.3400
8 ENDOCRINE TOXICITY 33 0.3235
9 IMMUNE-MEDIATED ENTEROCOLITIS 1171 0.3181
See all enriched reactions for IPILIMUMAB